Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment

Overview of attention for article published in Clinical Pharmacokinetics, February 2013

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 106 Dimensions

Readers on

mendeley: 149 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 49,767 followers.

RT @AlperDra: @drrakeshg1 @aalahmadmd @narrowQRS @guroledip @SchakrabartiEP @DursunAras2 https://t.co/WSkuRZ9AvQ https://t.co/eWiY4nemL1

Reply Repost Favourite

@drrakeshg1 @aalahmadmd @narrowQRS @guroledip @SchakrabartiEP @DursunAras2 https://t.co/WSkuRZ9AvQ https://t.co/eWiY4nemL1

Reply Repost Favourite

@brentnreed This might provide edoxaban with interesting advantage over apixaban. Subtle, but worthy to investigate. http://t.co/VAcRzeicsN

Reply Repost Favourite